Skip to content

Arvinas ARVN Professional Service Fees Payable

Professional Service Fees Payable at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$2.76M+58.8%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
$312.9K-0.1%
Nuvation Bio logo
Nuvation BioNUVB
$17.23M+6.1%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$518.11M-4.6%
Enterprise value$439.41M-7.1%
P/S5.8×+4.5×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Reported directly by Arvinas in its filing.

Tagged under the XBRL concept us-gaap:AccruedProfessionalFeesCurrent.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's professional service fees payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arvinas's professional service fees payable?
Arvinas (ARVN) reported professional service fees payable of $1.6M in Q1 2026.
How has Arvinas's professional service fees payable changed year-over-year?
Arvinas's professional service fees payable decreased by 48.4% year-over-year, from $3.1M to $1.6M.
What is the long-term trend for Arvinas's professional service fees payable?
Over 4 years (2021 to 2025), Arvinas's professional service fees payable has grown at a -6.9% compound annual growth rate (CAGR), from $1.2M to $900K.